0000899243-20-004288.txt : 20200212
0000899243-20-004288.hdr.sgml : 20200212
20200212170227
ACCESSION NUMBER: 0000899243-20-004288
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200210
FILED AS OF DATE: 20200212
DATE AS OF CHANGE: 20200212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Townsend Adam J.
CENTRAL INDEX KEY: 0001773588
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 20605206
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-10
0
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001773588
Townsend Adam J.
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE
WALTHAM
MA
02451
0
1
0
0
See Remarks
Common Stock
2020-02-10
4
A
0
9375
0.00
A
9375
D
Stock option (right to buy)
44.33
2020-02-10
4
A
0
56250
0.00
A
2030-02-09
Common Stock
56250
56250
D
Consists of shares of Common Stock issuable under 9,375 restricted stock units ("RSUs") granted pursuant to the Company's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. This RSU was granted on February 10, 2020 and will vest as to 25% of the shares underlying the RSU on the first anniversary of the grant, and 25% of the shares underlying the RSU on each anniversary of the grant thereafter through the fourth anniversary of the grant.
This option was granted on February 10, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
Chief Commercial Officer
/s/ David Watson, attorney-in-fact for Adam Townsend
2020-02-12